We're announcing our quarterly investor call on Thursday, November 19, 2026, at 5PM ET / 2PM PT to discuss @eXoZymes results for the third quarter 2026. A press release detailing these results will be issued prior to the call.
Investors can pre-register for the call here:
na2.hubs.ly/H08-y000 $EXOZ
James - Slack Capital retweeted
WTR’s Robert Sassoon on eXoZymes $EXOZ and how its cell-free platform delivered a 10-fold productivity gain in NCT manufacturing, plus the milestones to watch ahead of a 1H27 launch. Listen now, link in the replies.
Update from @Slack_Capital: What if @eXoZymes’ biggest opportunity isn’t a single molecule, but an AI-powered engine that combines computational design with cell-free biomanufacturing to repeatedly turn previously inaccessible chemistry into new products - and then do it all over again?
Read the full update from Slack Capital here:
na2.hubs.ly/H08fgX20 $EXOZ
eXoZymes Selects @CuriaCDMO as Commercial-Scale Manufacturing Partner for NCT
Paul Opgenorth, PhD, VP of Development and co-founder of @eXoZymes, elaborates “We have demonstrated the NCT process at pilot scale and substantially improved its productivity and economics. Transferring our entire integrated process - from enzyme production through the cell-free NCT reaction to product purification - into a commercial manufacturing environment represents an important validation of its maturity. Having visited Curia’s facilities in both Spain and Italy, I’m confident we have selected a partner with the technical capabilities and infrastructure to take this next step with us.”
Read the full press release here:
na2.hubs.ly/H07Gv5Q0 $EXOZ
James - Slack Capital retweeted
Replying to @eXoZymes @Slack_Capital
This is a really great research report. Definitely give it a read! @Slack_Capital
Research coverage from @WTR_Research: $EXOZ 2Q26 update - from platform validation to commercial execution
- The productivity result is the standout headline, beating management’s own hurdle.
- Scale-up and reproducibility have already been demonstrated independently
- The business model is becoming increasingly asset-light
- The strategy reset should strengthen the negotiating position of @eXoZymes
Read the full update here - accessible with a free login:
na2.hubs.ly/H07pTT40
We have been awarded a $2M @NIH grant to advance cannabinoid analogs for drug discovery:
• Expands pipeline beyond NCT into cannabinoid analogs
• Validates cell-free manufacturing platform
• Adds proprietary pharmaceutical assets without shareholder dilution
• Brings total non-dilutive funding to almost $20M
CEO @heltzen states: "The hardest part of cannabinoid drug discovery has always been a supply and purity problem - the most interesting molecules are the ones nature makes the least of. Our platform is built to change that. Once we can reliably produce the naturally occurring cannabinoids, we can engineer new-to-nature analogs around them that are more potent and better suited to pharmaceutical drug development than what is available today"
A second biosolution. Same platform. More shots on goal. 🚀
Full story here:
na2.hubs.ly/H06hQZx0 $EXOZ #cannabinoids #enzymes #exozymes #enzyme #cellfree #biosolution #biomanufacturing #exozyme
James - Slack Capital retweeted
James - Slack Capital retweeted
In this episode, Tyler Korman, Chief Scientific Officer and Co-Founder of eXoZymes, explains how AI-enhanced, cell-free enzyme technology could transform the future.
🎶tinyurl.com/2tb2s9zr
LinkedIn: linkedin.com/in/tyler-korman…
#Exozymes #Biomanufacturing #SyntheticBiology
James - Slack Capital retweeted
In this episode of Healthcare Happenings, @eXoZymes (Nasdaq: $EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon to discuss the company’s AI-driven, cell-free biomanufacturing platform.
🔹 Technology focus. “Exozyme” approach aims to address scalability challenges in synthetic biology.
🔹 Commercial strategy. Advancing programs in metabolic health and non-intoxicating cannabinoids.
🔹 Platform potential. Enables production of high-value molecules that have been difficult to scale historically.
🔹 Path forward. Focus on near-term milestones, regulatory dynamics, and a dual strategy of internal development and future licensing.
Listen to the full episode for additional insights into ExoZymes’ technology and growth strategy.
Podcast Platforms: pod.link/1795488592
Website: watertowerresearch.com/media…
$EXOZ #Biotech #SyntheticBiology #AI #HealthcareInnovation #Biomanufacturing #Investing #SmallCaps #WaterTowerResearch
James - Slack Capital retweeted
Good things are in motion. Our CEO @heltzen being interviewed by @michaelbspector at @Nasdaq today. $EXOZ
James - Slack Capital retweeted
Malcolm Bendall's #ThunderstormGenerator - Live and Uncut Demonstration, with a Control Generator, Live Gas Analysis and links to resources that can help you make or source your own, all in under 4 Minutes...!
#Plasmoid technology will change the world. Please share widely!! ⚡️🙏💫
youtu.be/KTzDKpqU7-k
#MalcolmBendall
#Plasma
#CombustionEngine
#Energy
#Environment
James - Slack Capital retweeted
A NEW ERA IN BIOMANUFACTURING IS HERE.
A solution to environmental and economic problems through cell-free AI catalyzed biosynthetic production of a wide range of chemicals, pharmaceuticals, nutraceuticals and even fuels.
$EXOZ
liebertpub.com/doi/10.1089/g…
James - Slack Capital retweeted
Managing Director Scott Macmillan shares insights on our newly announced joint venture with Al Mansour Holdings, a transformational partnership that unlocks significant opportunities and positions us for long-term success.
Hear directly from Scott 👇
#strategicpartnership
James - Slack Capital retweeted
This week, @slack_capital - an Australian investment research publication - has released an investment report on @eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, (@tylerkorman) focuses on the science behind our platform.
Full interview and report is available here:
exozymes.com/blog/slack-capi…
#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport $EXOZ
James - Slack Capital retweeted
NEW - Boston Dynamics presents the progress made in the movement capacity of its "humanoid robot" Atlas.
James - Slack Capital retweeted
Northstar $ROOF.V | $ROOOF Releases Empower Calgary Facility Construction & Commissioning Video Series Episode #4: Commissioning Commencement
▶️ Watch Here: hubs.li/Q039qrkH0
▶️ Full Release: hubs.li/Q039qBQM0
#circulareconomy #lowcarbon
James - Slack Capital retweeted
With a clear focus on developing the Cabora Bassa project, Invictus continues to pave the way for the future development of the Mukuyu gas field.
Hear the latest from Managing Director Scott Macmillan as he provides the outlook for the Company in 2025 👇
#CaboraBassa #Zimbabwe





















